New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
09:58 EDTMTU, OXM, PFG, SJM, COF, STI, TCP, NVS, FDO, BMRN, GPRE, LPL, SRE, LB, DG, ARCOOn The Fly: Analyst Upgrade Summary
Arcos Dorados (ARCO) upgraded to Buy from Underperform at BofA/Merrill... BioMarin (BMRN) upgraded to Outperform from Neutral at Credit Suisse... Capital One (COF) upgraded to Buy from Neutral at Nomura... Dollar General (DG) upgraded to Buy from Hold at Jefferies... Family Dollar (FDO) upgraded to Buy from Hold at Jefferies... J.M. Smucker (SJM) upgraded to Market Perform from Underperform at Wells Fargo... L Brands (LB) upgraded to Perform from Underperform at Oppenheimer... Novartis (NVS) upgraded to Equalweight from Underweight at Barclays... Principal Financial (PFG) upgraded to Equal Weight from Underweight at Morgan Stanley... Sempra Energy (SRE) upgraded to Buy from Neutral at ISI Group... TC PipeLines (TCP) upgraded to Equal Weight from Underweight at Barclays... Oxford Industries (OXM) upgraded to Buy from Neutral at Sidoti... LG Display (LPL) upgraded to Outperform from Neutral at Macquarie... SunTrust (STI) upgraded to Outperform from Market Perform at Keefe Bruyette... Mitsubishi UFJ (MTU) upgraded to Buy from Neutral at BofA/Merrill...Green Plains (GPRE) upgraded to Overweight from Equal Weight at Stephens.
News For ARCO;BMRN;COF;DG;FDO;SJM;LB;NVS;PFG;SRE;TCP;OXM;LPL;STI;MTU;GPRE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
July 21, 2015
05:20 EDTNVSNovartis backs FY15 revenue guidance of up mid-single digit
Subscribe for More Information
05:17 EDTNVSNovartis reports Q2 core EPS $1.27, consensus $1.24
Reports Q2 revenue $12.7B, consensus $12.44B. Further strengthening of USD impacted sales by -11% and core operating income by -13%. Growth Products, an indicator of the rejuvenation of the portfolio, contributed 35% of continuing operations net sales in Q2, and were up 24%. In Pharmaceuticals, Growth Products contributed 44% of division net sales in the quarter, and sales for these products were up 38%.
July 20, 2015
14:32 EDTBMRNFDA panel likely to review Sarepta, BioMarin drugs in November, TheStreet says
Subscribe for More Information
11:03 EDTBMRNSarepta rises after Roth says added data can keep it ahead of BioMarin
Subscribe for More Information
10:00 EDTSTIOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:07 EDTOXMMarquee Brands acquires Ben Sherman brand from Oxford Industries
Subscribe for More Information
08:47 EDTBMRNBioMarin reports Abrazo Phase 2 trial met threshold for tumor reduction
Subscribe for More Information
08:25 EDTNVSNovartis management to meet with JPMorgan
Subscribe for More Information
07:32 EDTNVSAlzheimer's Association to hold a conference
Subscribe for More Information
06:26 EDTSTISunTrust downgraded to Market Perform from Outperform at BMO Capital
Subscribe for More Information
July 19, 2015
12:50 EDTMTUJapanese blue chips could see gains of 30% or more, Barron's says
Subscribe for More Information
July 17, 2015
06:03 EDTSTISunTrust reports Q2 EPS 89c, consensus 81c
Reports Q2 revenue $2.2B, consensus $2.02B. Q2 was favorably impacted by a 3c per share discrete income tax benefit. Reports Q2 book value per share $42.46. Reports Q2 Tier 1 capital ratio 10.5%. Reports Q2 net charge-offs 0.26%.
July 16, 2015
17:16 EDTSJMJ.M. Smucker raises quarterly dividend 5% to 67c from 64c per share
Subscribe for More Information
15:02 EDTSTINotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's open, with earnings consensus, include General Electric (GE), consensus 28c... Honeywell (HON), consensus $1.49... Synchrony Financial (SYF), consensus 62c... SunTrust Banks (STI), consensus 81c... Progressive (PGR), consensus 55c... W.W. Grainger (GWW), consensus $3.05... Kansas City Southern (KSU), consensus $1.02... JB Hunt Transport (JBHT), consensus 90c... Autoliv (ALV), consensus $1.55... Comerica (CMA), consensus 75c... First Horizon (FHN), consensus 20c.
09:30 EDTCOFHershey names Peter Horst as Chief Marketing Officer effective July 27Capital One
Hershey (HSY) announced that marketing veteran Peter Horst will join the company as Senior Vice President, Chief Marketing Officer, effective July 27. Horst joins Hershey from Capital One (COF) where he served as Senior Vice President, Brand Marketing.
08:54 EDTPFGBofA/Merrill U.S. life insurance analyst holds analyst/industry conference call
U.S. Life Insurance Analyst Weiss, along with Jill Hoffman, VP of Government Affairs and Felicia Smith, VP & Senior Counsel for Regulatory Affairs from the Financial Services Roundtable, discuss the Labor Department's recent proposal to impose fiduciary standards on the sale of retirement products on an Analyst/Industry conference call to be held on July 20 at 11 am.
July 15, 2015
09:35 EDTARCOArcos Dorados downgraded to Sell from Neutral at Citi
Subscribe for More Information
07:58 EDTNVSAnalysts break down impact of $7.2B Receptos buyout
After Celgene (CELG) announced last night that the company has agreed to acquire Receptos (RCPT) for $232 per share in cash, or a total of about $7.2B net of cash acquired, research firms have chimed in with their opinions on how the proposed deal may impact others in the biotech space. Receptos key asset is Ozanimod, which is being studied in Phase III trials for relapsing multiple sclerosis and ulcerative colitis. DERIVATIVE CALLS: Piper Jaffray analyst Edward Tenthoff told investors that he views Celgene's deal for Receptos as good for Arena Pharmaceuticals (ARNA). The analyst notes that Arena's APD334 is already showing dose-dependent decreases in circulating lymphocyte counts and that the company will initiate Phase II studies in ulcerative colitis and Crohn's disease this year. Tenthoff reiterates an Overweight rating and $7.50 price target on Arena, which has a market capitalization around $1B and closed yesterday up 8c to $4.47. In its own note to investors this morning, Nomura said Celgene's deal could put downward pressure on Biogen's (BIIB) long-term multiple sclerosis estimates. Nomura's M. Ian Somaiya contended that one-year Phase II efficacy data for Ozanimod looked as good as Novartis’s (NVS) Gilenya and Biogen's Tecfidera’s Phase III at year 2. Somaiya also wondered if rival Gilead (GILD) could be "looking for something bigger" than Receptos for its own deal, telling investors that the firm views Incyte (INCY) as Gilead's most likely takeout target. Incyte's shares closed up $4.46 at $117.46 yesterday, giving the company a market cap of about $20B. RIVAL BID?: Wedbush analyst Liana Moussatos believes another bidder may seek to acquire Receptos, noting that she previously estimated Receptos could be valued at $348 per share, or about $10.9B, in a buyout. Moussatos noted that Celgene said it expects annual peak sales for Ozanimod to reach about $4B-$6B for RMS and UC, making its acquisition price of $7.2BN only a bit more than about 1X peak sales without accounting for other possible indications or the rest of its pipeline. Moussatos told investors she sees "plenty" of potential upside to justify a rival bidder stepping in and reiterated the firm's Outperform rating on Receptos shares. PRICE ACTION: In pre-market trading, Receptos rose 10% to $228.61 while Gilead gained 1.4% to about $119 per share.
07:36 EDTSTISunTrust July volatility elevated into Q2 and outlook
Subscribe for More Information
06:15 EDTCOFCapital One reports June net charge-offs 3.23% vs. 3.39% last month
Reports June 30-plus day performing delinquency rate 2.84% vs. 2.74% last month.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use